Dispatch Bio
Focus: Dispatch Bio is a public-stage immuno-oncology biotech company focused on CAR T-cell therapy and T-cell armoring strategies for oncology. The company is headquartered in San Francisco and maintains an active pipeline in cell therapy innovation.
Profile data last refreshed 6h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
8
Should You Work at Dispatch Bio?
AI assessmentDispatch Bio represents a speculative mid-stage bet in a high-potential immuno-oncology niche, best suited for early-career scientists or specialists willing to accept execution risk for innovation upside.
Why Work Here
- Active presence in cutting-edge CAR T-cell and cell therapy space, with recent ASGCT 2026 presentation on SEND T-cell armoring strategy signaling ongoing R&D momentum.
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Dispatch Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.